Eli Lilly Starts World’s First Human Trial of Antibody for COVID-19

Eli Lilly has dosed its first patients in the world’s first trial of an investigational antibody designed to treat COVID-19.

The phase 1 trial  of  LY-CoV555 will investigate the safety and tolerability of a single dose administered to hospitalized COVID-19 patients.

LY-CoV555 is the first investigational treatment to emerge from the company’s development collaboration with AbCellera. Results of the trial are anticipated by the end of the month.